- > Media & Investors
- > Media Relations
- > Press Releases
- > Daiichi Sankyo Announces New Oxycodone Extended Release Tablets "Daiichi Sankyo" for Sustained Cancer Pain Treatment
For Immediate Release
Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: George Nakayama, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Daiichi Sankyo Announces New Oxycodone Extended Release Tablets "Daiichi Sankyo" for Sustained Cancer Pain Treatment
Tokyo, Japan (March 8, 2017) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has launched new generic oxycodone extended release formulations to treat sustained cancer pain: Oxycodone Extended Release 5 mg, 10 mg, 20 mg and 40 mg "Daiichi Sankyo" (date of approval: August 15, 2016; date of listing in the NHI reimbursement price list in Japan: December 9, 2016).
This oxycodone extended release tablet is an opioid analgesic providing the degree of analgesia prescribed for various cancers with moderate to severe pain, and the first tablet generic for an oxycodone extended release formulation. Our domestic subsidiary, Daiichi Sankyo Propharma Co., Ltd. (manufacturing and marketing) manufactures from drug substance to formulation using our GWATab® technology*.
Daiichi Sankyo expects this drug to be able to contribute to all patients and medical staff by offering a new therapeutic option.
Original brand name
Oxycodone Extended Release tablets 5mg "Daiichi Sankyo"
Oxycodone Extended Release tablets 10mg "Daiichi Sankyo"
Oxycodone Extended Release tablets 20mg "Daiichi Sankyo"
Oxycodone Extended Release tablets 40mg "Daiichi Sankyo"
Sustained cancer pain treatment
*GWATab® (Gelling WAter soluble polymer matrix Tablet) technology is proprietary technology that combines a drug substance with a water-soluble polymer, releasing medication along a wide range of the gastrointestinal tract after dosing, for sustained drug efficacy.
About Daiichi Sankyo Opioid Analgesics
Daiichi Sankyo contributes to the total care for the life of patients with cancer by producing opioid analgesics.
In Japan, Daiichi Sankyo has filed applications for the manufacturing and marketing of hydromorphone hydrochloride formulations (extended release tablets, immediate release tablets, and injection), which are potent opioid, narcotic analgestics with high medical needs for patients. Daiichi Sankyo also received approval for oxycodone immediate release tablets in February 2017.
Daiichi Sankyo believes that expanding our product lineup of opioid analgesics helps patients with cancer to improve their quality of life by relieving pain and supports patients living with cancer.